Wilson Sonsini Goodrich & Rosati advised Iambic Therapeutics on the transaction. Iambic Therapeutics (Iambic), a clinical-stage biotechnology company, announced the closing of an oversubscribed $50 million...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction. Iambic Therapeutics announced the closing of an oversubscribed $100 million Series B financing. The round was co-led by...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Codex DNA on the deal. Codex DNA, Inc. (Nasdaq: DNAY) announced the closing of its initial public offering of 7,666,664...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati, P.C. advised Nautilus Biotechnology, while Kirkland & Ellis LLP, working alongside Ogier, advised Arya III on the deal. Latham & Watkins...
You must be a Standard 1 Year member to access this content.
